CA2691214A1 - Therapie a base d'inhibiteurs de cytokine - Google Patents

Therapie a base d'inhibiteurs de cytokine Download PDF

Info

Publication number
CA2691214A1
CA2691214A1 CA2691214A CA2691214A CA2691214A1 CA 2691214 A1 CA2691214 A1 CA 2691214A1 CA 2691214 A CA2691214 A CA 2691214A CA 2691214 A CA2691214 A CA 2691214A CA 2691214 A1 CA2691214 A1 CA 2691214A1
Authority
CA
Canada
Prior art keywords
moiety
target protein
planar
attached
pocket
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2691214A
Other languages
English (en)
Inventor
Constance A. Crowley
Nancy G. J. Delaet
Justin Ernst
Carrie Gail Grove
Bonnie Hepburn
Bernard King
Christopher J. Larson
Stephen Miller
Kent Pryor
Lewis J. Shuster
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
iTherX Pharmaceuticals Inc
Original Assignee
Kemia, Inc.
Constance A. Crowley
Nancy G. J. Delaet
Justin Ernst
Carrie Gail Grove
Bonnie Hepburn
Bernard King
Christopher J. Larson
Stephen Miller
Kent Pryor
Lewis J. Shuster
Itherx Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kemia, Inc., Constance A. Crowley, Nancy G. J. Delaet, Justin Ernst, Carrie Gail Grove, Bonnie Hepburn, Bernard King, Christopher J. Larson, Stephen Miller, Kent Pryor, Lewis J. Shuster, Itherx Pharmaceuticals, Inc. filed Critical Kemia, Inc.
Publication of CA2691214A1 publication Critical patent/CA2691214A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2691214A 2006-06-09 2007-06-06 Therapie a base d'inhibiteurs de cytokine Abandoned CA2691214A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US81226806P 2006-06-09 2006-06-09
US60/812,268 2006-06-09
US83307806P 2006-07-24 2006-07-24
US60/833,078 2006-07-24
US83527006P 2006-08-03 2006-08-03
US60/835,270 2006-08-03
PCT/US2007/070547 WO2007146712A2 (fr) 2006-06-09 2007-06-06 Thérapie à base d'inhibiteurs de cytokine

Publications (1)

Publication Number Publication Date
CA2691214A1 true CA2691214A1 (fr) 2007-12-21

Family

ID=38832677

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2691214A Abandoned CA2691214A1 (fr) 2006-06-09 2007-06-06 Therapie a base d'inhibiteurs de cytokine

Country Status (8)

Country Link
EP (1) EP2035005A4 (fr)
AR (1) AR061273A1 (fr)
AU (1) AU2007257959A1 (fr)
CA (1) CA2691214A1 (fr)
CL (1) CL2007001670A1 (fr)
PE (1) PE20080935A1 (fr)
TW (1) TW200814998A (fr)
WO (1) WO2007146712A2 (fr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0707719A2 (pt) 2006-02-10 2011-05-10 Summit Corp Plc uso de um composto ou de um sal farmaceuticamente aceitÁvel do mesmo
US7989459B2 (en) 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
TW200831104A (en) 2006-10-04 2008-08-01 Pharmacopeia Inc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US7902187B2 (en) 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
WO2008043019A1 (fr) 2006-10-04 2008-04-10 Pharmacopeia, Inc Dérivés de 2-(benzimidazolyl) purine substitués en position 8 pour immunosuppression
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US7902248B2 (en) 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
CN101801187B (zh) * 2007-07-13 2014-07-23 得克萨斯系统大学评议会 大麻素受体的杂环调节剂
PE20090510A1 (es) 2007-08-03 2009-05-22 Summit Corp Plc Combinaciones de drogas para el tratamiento de la distrofia muscular de duchenne
CA3034994A1 (fr) 2008-06-03 2009-12-10 Intermune, Inc. Composes et procedes de traitement des troubles inflammatoires et fibrotiques
US20110230497A1 (en) * 2008-11-07 2011-09-22 H. Lundbeck A/S Biologically active amides
CN102548986A (zh) 2009-06-05 2012-07-04 链接医药公司 氨基吡咯烷酮衍生物及其用途
WO2011063076A1 (fr) * 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Méthodes de traitement du virus de l'hépatite c avec des composés d'oxo-acétamide
ES2550033T3 (es) * 2009-12-23 2015-11-04 Ratiopharm Gmbh Forma de dosificación farmacéutica sólida de ticagrelor
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
SG10201502484SA (en) 2010-03-30 2015-05-28 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
EP3045452A1 (fr) 2010-04-22 2016-07-20 Vertex Pharmaceuticals Inc. Procédé de production de composés cycloalkyle-carboxamide-indole
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
CN104436197A (zh) 2011-10-21 2015-03-25 艾伯维公司 至少两种直接作用抗病毒剂的组合产品
SE1450019A1 (sv) 2011-10-21 2014-01-10 Abbvie Inc Förfaranden för att behandla HCV innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
SI2968297T1 (sl) 2013-03-15 2019-02-28 Verseon Corporation Multisubstituirane aromatske skupine kot inhibitorji serinske proteaze
KR102373700B1 (ko) 2014-04-02 2022-03-11 인터뮨, 인크. 항섬유성 피리디논
SG11201607670XA (en) 2014-04-15 2016-10-28 Vertex Pharma Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
AU2015317522A1 (en) 2014-09-17 2017-03-23 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
WO2016094688A1 (fr) 2014-12-10 2016-06-16 Massachusetts Institute Of Technology Dérivés fusionnés de 1,3-azole utiles pour le traitement de maladies prolifératives
SG11201706411YA (en) 2015-02-27 2017-09-28 Verseon Corp Substituted pyrazole compounds as serine protease inhibitors
JP2018524302A (ja) * 2015-06-12 2018-08-30 ユニバーシティ オブ グリニッジ インターフェロン‐γ阻害剤としてのトリアジン誘導体
TW201718581A (zh) 2015-10-19 2017-06-01 英塞特公司 作為免疫調節劑之雜環化合物
TWI763641B (zh) 2015-11-19 2022-05-11 美商英塞特公司 作為免疫調節劑之雜環化合物
CR20180328A (es) 2015-12-15 2018-08-09 Astrazeneca Ab Compuestos de isoindol
MX2018007774A (es) 2015-12-22 2018-11-09 Incyte Corp Compuestos heterociclicos como inmunomoduladores.
CA3012846A1 (fr) 2016-02-16 2017-08-24 Massachusetts Institute Of Technology Liants de max comme modulateurs de myc et leurs utilisations
CA3022119A1 (fr) 2016-04-28 2017-11-02 Emory University Compositions therapeutiques a base de nucleotides et nucleosides contenant un alcyne et utilisations associees
AR108396A1 (es) 2016-05-06 2018-08-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
US20170342060A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
MY195671A (en) * 2016-06-08 2023-02-03 Support Venture Gmbh Pharmaceutical Combinations for Treating Cancer
LT3472167T (lt) 2016-06-20 2022-11-10 Incyte Corporation Heterocikliniai junginiai kaip imunomoduliatoriai
US20180016260A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
MA46045A (fr) 2016-08-29 2021-04-28 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
PL3558997T3 (pl) 2016-12-20 2021-07-19 Astrazeneca Ab Związki amino-triazolopirydyny i ich zastosowanie w leczeniu nowotworu złośliwego
EP3558989B1 (fr) 2016-12-22 2021-04-14 Incyte Corporation Dérivés de triazolo[1,5-a]pyridine en tant qu'immunomodulateurs
ES2934230T3 (es) 2016-12-22 2023-02-20 Incyte Corp Derivados de benzooxazol como inmunomoduladores
KR102641030B1 (ko) 2016-12-22 2024-02-29 인사이트 코포레이션 Pd-l1 내재화 유도제로서의 테트라하이드로 이미다조[4,5-c]피리딘 유도체
WO2018119221A1 (fr) 2016-12-22 2018-06-28 Incyte Corporation Dérivés pyridine utilisés en tant qu'immunomodulateurs
US11242327B2 (en) * 2017-05-15 2022-02-08 Recurium Ip Holdings, Llc Analgesic compounds
JP2020524660A (ja) 2017-06-14 2020-08-20 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Ｒｏｒ−ガンマモジュレーターとして有用な２，３−ジヒドロイソインドール−１−カルボキサミド
CN107474043A (zh) * 2017-09-13 2017-12-15 厦门稀土材料研究所 烟酸衍生物及其制备方法与用途
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
ES2927715T3 (es) 2017-10-05 2022-11-10 Fulcrum Therapeutics Inc Inhibidores de la quinasa p38 reducen la expresión de dux4 y de los genes que le siguen para el tratamiento de la FSHD
US11667651B2 (en) 2017-12-22 2023-06-06 Hibercell, Inc. Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
EP4212529A1 (fr) 2018-03-30 2023-07-19 Incyte Corporation Composés hétérocycliques utilisés comme immunomodulateurs
CN112752756A (zh) 2018-05-11 2021-05-04 因赛特公司 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物
US11292782B2 (en) 2018-11-30 2022-04-05 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
EP3886854A4 (fr) 2018-11-30 2022-07-06 Nuvation Bio Inc. Composés pyrrole et pyrazole et leurs procédés d'utilisation
CN111825605B (zh) * 2019-04-19 2023-03-31 中国科学院上海药物研究所 芳基酮酰胺类化合物及其制备方法和用途
US11753406B2 (en) 2019-08-09 2023-09-12 Incyte Corporation Salts of a PD-1/PD-L1 inhibitor
BR112022005826A2 (pt) 2019-09-30 2022-06-21 Incyte Corp Compostos de pirido[3,2-d]pirimidina como imunomoduladores
CA3159766A1 (fr) * 2019-11-05 2021-05-14 Dermira, Inc. Antagonistes de mrgprx2 pour le traitement de troubles inflammatoires
BR112022009031A2 (pt) 2019-11-11 2022-10-11 Incyte Corp Sais e formas cristalinas de um inibidor de pd-1/pd-l1
CA3164134A1 (fr) 2019-12-06 2021-06-10 Vertex Pharmaceuticals Incorporated Tetrahydrofuranes substitues en tant que modulateurs de canaux sodiques
AR124001A1 (es) 2020-11-06 2023-02-01 Incyte Corp Proceso para fabricar un inhibidor pd-1 / pd-l1 y sales y formas cristalinas del mismo
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
WO2022099018A1 (fr) 2020-11-06 2022-05-12 Incyte Corporation Procédé de préparation d'un inhibiteur de pd-1/pd-l1
CN113209112B (zh) * 2021-02-06 2021-12-24 广州市朝利良生物科技有限公司 基于ace2与s蛋白结合靶点的抗新型冠状病毒药物及其应用
UY39800A (es) 2021-06-04 2023-01-31 Vertex Pharma N–(hidroxialquil (hetero)aril) tetrahidrofuran carboxamidas como moduladores de canales de sodio
WO2024059220A2 (fr) * 2022-09-15 2024-03-21 Vanderbilt University Composés à noyau 6,5 southwestern utilisés en tant que modulateurs allostériques négatifs du mglu5 et leurs méthodes de production et d'utilisation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004530690A (ja) * 2001-05-16 2004-10-07 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症性薬剤として有用なジアリールウレア誘導体
BRPI0414313A (pt) * 2003-09-11 2006-11-07 Kemia Inc inibidores de citocinas

Also Published As

Publication number Publication date
AU2007257959A1 (en) 2007-12-21
TW200814998A (en) 2008-04-01
AR061273A1 (es) 2008-08-13
EP2035005A2 (fr) 2009-03-18
WO2007146712A2 (fr) 2007-12-21
EP2035005A4 (fr) 2011-07-06
CL2007001670A1 (es) 2008-01-18
WO2007146712A3 (fr) 2008-11-27
PE20080935A1 (es) 2008-08-02

Similar Documents

Publication Publication Date Title
CA2691214A1 (fr) Therapie a base d'inhibiteurs de cytokine
WO2007058990A2 (fr) Therapie a base d’inhibiteurs de cytokine
US7087608B2 (en) Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
WO2007075896A2 (fr) Inhibiteurs de cytokine heterocycliques
JP4895811B2 (ja) サイトカイン阻害剤
WO2007056016A2 (fr) Inhibiteurs de cytokine bisamide
RU2632900C2 (ru) Гетероциклические амины и их применение
WO2008089034A2 (fr) Inhibiteurs de cytokine
WO2008021388A1 (fr) Dérivés hétéroaryles en tant qu'inhibiteurs des cytokines
WO2006091862A2 (fr) Inhibiteurs des cytokines et utilisation therapeutique
US8614222B2 (en) Methods of preventing and treating low bone mass diseases
AU2001248324A1 (en) Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
ZA200707095B (en) Cytokine inhibitors
EP1293213A1 (fr) Agents prophylactiques/therapeutiques contre le stress postoperatoire
JP2007513872A (ja) Ｃｂ１拮抗作用を示す化合物の新規の医学的用途および前記化合物を伴う組み合わせ治療
TWI542350B (zh) Ｋｍｕｐ複合銨鹽類及高分子聚合物之改善高脂血及體重失衡療效
BRPI0612582A2 (pt) combinação de compostos orgánicos
US20220040162A1 (en) Compositions comprising a crac inhibitor and a corticosteroid and methods of use thereof
KR20100021444A (ko) 플루오로퀴놀론을 사용하여 염증을 조절하기 위한 조성물 및 방법
KR101170175B1 (ko) 사이토킨 억제제
CN106220562A (zh) 两种喹啉环类药物的新用途

Legal Events

Date Code Title Description
FZDE Dead